Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$8.48 USD
-0.63 (-6.87%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $8.47 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Price, Consensus and EPS Surprise
MRVI 8.48 -0.63(-6.87%)
Will MRVI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRVI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRVI
Maravai (MRVI) Advances in RNA Research With New Collaboration
Are Options Traders Betting on a Big Move in Maravai LifeSciences (MRVI) Stock?
MRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zynex Inc. (ZYXI) Q3 Earnings Match Estimates
PetIQ (PETQ) Moves 5.7% Higher: Will This Strength Last?
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Other News for MRVI
Stifel Nicolaus Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)
Maravai Lifesciences Holdings (MRVI) Receives a Buy from RBC Capital
Buy Rating Affirmed for Maravai Lifesciences Amid Strong Growth Prospects and Operational Investments
Maravai Lifesciences price target raised by $2.50 at UBS, here's why
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2024 Earnings Call Transcript